Sulforaphane prevents human platelet aggregation through inhibiting the phosphatidylinositol 3-kinase/Akt pathway

Thrombosis and Haemostasis

Volumn 109, Issue 6, 2013, Pages 1120-1130

  Chuang, Wen Ying ^a   Kung, Po Hsiung ^a   Kuo, Chih Yun ^a   Wu, Chin Chung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Phosphatidylinositol 3 Kinase; Platelet aggregation; Sulforaphane; Ubi quitination

Indexed keywords

15 HYDROXY 11ALPHA, 9ALPHA EPOXYMETHANOPROSTA 5, 13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COLLAGEN; CYCLIC AMP; CYCLIC GMP; ISOBUTYLMETHYLXANTHINE; NITROPRUSSIDE SODIUM; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROSTAGLANDIN E1; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN P85; PROTEIN TYROSINE KINASE; PROTEINASE ACTIVATED RECEPTOR 1; SULFORAPHANE; THROMBIN; UBIQUITIN; UNCLASSIFIED DRUG; WORTMANNIN;

ARTERY THROMBOSIS; ARTICLE; CELL FRACTIONATION; CONTROLLED STUDY; CYTOLYSIS; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; NORMAL HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SPECTROFLUOROMETRY; THROMBOCYTE AGGREGATION; UBIQUITINATION; WESTERN BLOTTING;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; BLOOD PLATELETS; CALCIUM; CATTLE; ENZYME ACTIVATION; HUMANS; ISOTHIOCYANATES; PHOSPHATIDYLINOSITOL 3-KINASES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, PAR-1; SIGNAL TRANSDUCTION; THROMBOXANE A2; TYROSINE; VASOCONSTRICTOR AGENTS; VEGETABLES;

EID: 84878623605     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-09-0636     Document Type: Article

References (50)

1. Verkerk R, Schreiner M, Krumbein A, et al. Glucosinolates in Brassica vegetables: the influence of the food supply chain on intake, bioavailability and human health. Mol Nutr Food Res 2009; 53: S219.
2. Cheung KL, Kong AN. Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chaemoprevention. AAPS J 2010; 12: 87-97.
3. Thimmulappa RK, Mai KH, Srisuma S, et al. Identification of Nrf2-regulated genes induced by the chaemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002; 62: 5196-5203.
4. Clarke JD, Dashwood RH, Ho E. Multi-targeted prevention of cancer by sulfor-aphane. Cancer Lett 2008; 269: 291-304.
5. Keum YS. Regulation of the Keap1/Nrf2 system by chaemopreventive sulfor-aphane: implications of posttranslational modifications. Ann NY Acad Sci 2011; 1229: 184-189.
6. Lin HJ, Probst-Hensch NM, Louie AD, et al. Glutathione transferase null genotype, broccoli, and lower prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1998; 7: 647-652.
7. Cotton SC, Sharp L, Little J, et al. Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 2000; 151: 7-32.
8. Zhang Y. Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. Mutat Res 2004; 555: 173-190.
9. Dinkova-Kostova AT, Kostov RV. Glucosinolates and isothiocyanates in health and disease. Trends Mol Med 2012; 18: 337-347.
10. Wu L, Noyan Ashraf MH, Facci M, et al. Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system. Proc Natl Acad Sci USA 2004; 101: 7094-7099.
11. Piao CS, Gao S, Lee GH, et al. Sulforaphane protects ischaemic injury of hearts through antioxidant pathway and mitochondrial K(ATP) channels. Pharmacol Res 2010; 61: 342-348.
12. Zhao J, Kobori N, Aronowski J, et al. Sulforaphane reduces infarct volume following focal cerebral ischaemia in rodents. Neurosci Lett 2006; 393: 108-112.
13. Zakkar M, Van der Heiden K, Luongle A, et al. Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state. Arterioscler Thromb Vasc Biol 2009; 29: 1851-1857.
14. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010; 9: 154-169.
15. Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011; 106: 827-838.
16. Wei AH, Schoenwaelder SM, Andrews RK, et al. New insights into the haemostatic function of platelets. Br J Haematol 2009; 147: 415-430.
17. Li Z, Delaney MK, O'Brien KA, et al. Signalling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010; 30: 2341-2349.
18. Gratacap M P, Guillermet-Guibert J, Martin V, et al. Regulation and roles of PI3Kβ, a major actor in platelet signalling and functions. Adv Enzyme Regul 2011; 51: 106-116.
19. Jackson SF, Schoenwaelder SM. Type I phosphoinositide 3-kinases: potential antithrombotic targets? Cell Mol Life Sci 2006; 63: 1085-1090.
20. Wu CC, Wang WY, Wei CK, et al. Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets. Thromb Haemost 2011; 105: 88-95.
21. Séverin S, Gratacap MP, Lenain N, et al. Deficiency of Src homology 2 domain-containing inositol 5-phosphatase 1 affects platelet responses and thrombus growth. J Clin Invest 2007; 117: 944-952.
22. Meyer dos Santos S, Klinkhardt U, Schneppenheim R, et al. Using ImageJ for the quantitative analysis of flow-based adhesion assays in real-time under physiologic flow conditions. Platelets 2010; 21: 60-66.
23. Wu CC, Wu CI, Wang WY, et al. Low concentrations of resveratrol potentiate the antiplatelet effect of prostaglandins. Planta Med 2007; 73: 439-443.
24. 3H]arachidonic acid and changes in cytosolic free calcium in fura-2-loaded human platelets stimulated by ion-omycin and collagen. Biochem J 1986; 235: 869-877.
25. Mancini F, Rigacci S, Berti A, et al. The low-molecular-weight phosphotyrosine phosphatase is a negative regulator of FcgammaRIIA-mediated cell activation. Blood 2007; 110: 1871-1878.
26. Wang WY, Hsieh PW, Wu YC, et al. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol 2007; 74: 601-611.
27. Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011; 72: 634-646.
28. Trumel C, Payrastre B, Plantavid M, et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 4156-4165.
29. Kim S, Jin J, Kunapuli S P. Relative contribution of G-protein-coupled pathways to protease-activated receptor-mediated Akt phosphorylation in platelets. Blood 2006; 107: 947-954.
30. Elzagallaai A, Rosé SD, Trifaró JM. Platelet secretion induced by phorbol esters stimulation is mediated through phosphorylation of MARCKS: a MARCKS-de-rived peptide blocks MARCKS phosphorylation and serotonin release without affecting pleckstrin phosphorylation. Blood 2000; 95: 894-902.
31. Fang D, Liu YC. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol 2001; 2: 870-875.
32. Fang D, Wang HY, Fang N, et al. Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J Biol Chem 2001; 276: 4872-4878.
33. Balasubramanian S, Chew YC, Eckert RL. Sulforaphane suppresses polycomb group protein level via a proteasome-dependent mechanism in skin cancer cells. Mol Pharmacol 2011; 80: 870-878.
34. Busso CS, Iwakuma T, Izumi T. Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signalling pathway. Oncogene 2009; 28: 1616-1625.
35. Dangelmaier CA, Quinter PG, Jin J, et al. Rapid ubiquitination of Syk following GPVI activation in platelets. Blood 2005; 105: 3918-3924.
36. Hu R, Hebbar V, Kim BR, et al. In vivo pharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat. J Pharmacol Exp Ther 2004; 310: 263-271.
37. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005; 11: 507-514.
38. Martin V, Guillermet-Guibert J, Chicanne G, et al. Deletion of the p110beta iso-form of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 2010; 115: 2008-2013.
39. Garcia A, Kim S, Bhavaraju K, et al. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Biochem J 2010; 429: 369-377.
40. Kovacsovics TJ, Bachelot C, Toker A, et al. Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation. J Biol Chem 1995; 270: 11358-11366.
41. Schoenwaelder SM, Ono A, Nesbitt WS, et al. Phosphoinositide 3-kinase p110 beta regulates integrin alpha IIb beta 3 avidity and the cellular transmission of contractile forces. J Biol Chem 2010; 285: 2886-2896.
42. Pasquet JM, Bobe R, Gross B, et al. A collagen-related peptide regulates phosp-holipase Cγ2 via phosphatidylinositol 3-kinase in human platelets. Biochem J 1999; 342: 171-177.
43. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol 2005; 6: 599-609.
44. Brophy TM, Raab M, Daxecker H, et al. RN181, a novel ubiquitin E3 ligase that interacts with the KVGFFKR motif of platelet integrin alpha(IIb)beta3. Bio-chem Biophys Res Commun 2008; 369: 1088-1093.
45. Lin AE, Mak T W. The role of E3 ligases in autoimmunity and the regulation of autoreactive T cells. Curr Opin Immunol 2007; 19: 665-673.
46. Schwartz AL, Ciechanover A. Targeting proteins for destruction by the ubiqui-tin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 2009; 49: 73-96.
47. Komander D, Clague MJ, Urbé S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009; 10: 550-563.
48. Mi L, Hood BL, Stewart NA, et al. Identification of potential protein targets of isothiocyanates by proteomics. Chem Res Toxicol 2011; 24: 1735-1743.
49. Lee BH, Lee MJ, Park S, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010; 467: 179-184.
50. Hussain S, Foreman O, Perkins SL, et al. The de-ubiquitinase UCH-L1 is an on-cogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signalling. Leukemia 2010; 24: 1641-1655.